Ginkgo Bioworks Holdings, Inc. DNA
10.66
0.41
4.00%
as of 25 Sep
- Market cap
- $683.6M
- P/E
- 0.0×
Follow DNA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (56.29%) | (55.82%) | (51.08%) | (50.02%) |
+8 more TTM periods Free account |
|
| (26.19%) | (26.17%) | (25.05%) | (25.43%) | ||
ROIC |
(161.94%) | (274.12%) | (229.21%) | (212.39%) | |
Return on Tangible Assets |
(69.74%) | (61.70%) | (57.57%) | (59.84%) | |
Average Days of Receivables |
35.87 | 48.87 | 52.03 | 50.99 | |
Free Cash Flow per Share |
(2.81) | (2.81) | (3.21) | (3.36) | |
Free Cash Flow |
(174.23) | (167.63) | (178.15) | (187.13) | |
Capital Expenditures |
(3.98) | (1.40) | (7.09) | (21.31) | |
Piotroski F-Score |
1.00 | 3.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(23.56%) | (20.36%) | (18.37%) | (16.23%) | |
Accounts Receivable Turnover |
7.33 | 6.38 | 7.29 | 6.91 | |
Accounts Payable Turnover |
4.07 | 3.33 | 3.80 | 2.42 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
82.58 | 129.46 | 82.10 | 122.50 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
162.82% | 147.14% | 143.27% | 168.71% | |
Selling, General and Administrative Expense of Revenue |
133.81% | 119.81% | 107.72% | 110.56% | |
Share Based Compensation of Revenue |
51.96% | 52.85% | 47.92% | 50.66% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.59 | 0.55 | 0.55 | 0.49 | |
Depreciation/Fixed assets |
0.32 | 0.33 | 0.33 | 0.35 | |
Capex/Depreciation |
(0.08) | (0.03) | (0.13) | (0.35) | |
Revenue per Share |
2.13 | 2.54 | 3.07 | 2.88 | |
Operating CF per Share |
(2.74) | (2.79) | (3.08) | (2.98) | |
Capex per Share |
(0.06) | (0.02) | (0.13) | (0.38) | |
Capex to Sales |
0.03 | 0.01 | 0.04 | 0.13 | |
Net Profit Margin |
(219.60%) | (201.05%) | (183.81%) | (212.15%) |
Columns are period end dates